Syngas Fermentation Patents: Who Leads, Where the Gaps Are 2026
- 75.5% of all 257 records sit with just five assignees, so most of the field's claim space around cell removal and product capture is already staked out by a small group.
- Filing peaked in 2017 at 38 and the 2021-to-2024 span shows a 33% pullback in complete-year filings, though 2025-2026 counts are still filling in under publication lag.
- C12M bioreactor claims (41.2%) and C12N microorganism claims (40.5%) run almost neck and neck, while downstream separation-adjacent classes like C01B and C25B stay under 12% each.
Filing growth compares 2021 (6 records) with 2024 (4) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 257 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This review covers 257 published records filed between 2015 and mid-2026 that combine syngas, gas or acetogenic fermentation with a product-recovery step — cell removal, broth clarification, product capture, solvent extraction, phase separation or recovery yield — and that carry an IPC classification in C12P7/40, C12P7/54 or C12M1/04. The scope is narrow by design: it isolates the recovery and separation side of gas fermentation rather than the broader microbial-strain or bioreactor-design literature.
Records are drawn from major receiving offices including the United States, the EPO, Canada, WIPO's PCT route, Australia and Malaysia, giving a reasonably complete picture of where applicants have sought protection rather than just where they are headquartered.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 257-record dataset: how filing activity has moved year over year, and how records distribute across IPC subclasses. Because a single record can carry several IPC classes, the technology shares add up to more than 100%.
Filing activity, 2015-2026
Filings peaked at 38 in 2017. Complete-year data show 6 filings in 2021 falling to 4 in 2024, a 33% decline over that span; 2025 and 2026 are undercounted because publication typically lags filing by around 18 months.
Technology composition by IPC subclass
Every record falls under C12P (fermentation and enzymatic synthesis) by definition of the search scope. Bioreactor apparatus (C12M, 41.2%) and microorganism/genetic engineering claims (C12N, 40.5%) dominate, while inorganic-compound (C01B), electrolytic (C25B), animal feed (A23K) and fuel (C10L) classes each sit under 12% of records.
Shares are the percentage of the 257 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Syngas Fermentation Product Recovery with Eureka
This page is one run against one query. Ask Eureka your own question about syngas fermentation product recovery and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this space
WO2024228166A1 — Acetogenic fermentation of carbon monoxide gas
This invention relates to acetogenic gas fermentation, specifically of carbon monoxide (CO) gas and gas mixtures containing the same, typically comprised in synthesis gas or industrial waste gases in fluctuating quantities, using acetogens such as Thermoanaerobacter kivui. The invention finds particular application in industrial fermentation of the gaseous C1 substrates CO and CO2, as well as H2 and any mixture thereof, in bioreactors.Filed by CIRCE Biotechnologie GmbH and published November 2024, this record sits at the newer edge of the dataset and signals continued interest in thermophilic acetogen strains beyond the Clostridium lineage that dominates the oldest, most-cited filings.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5593886A | Clostridium stain which produces acetic acid from waste gases | 743 |
| 2 | US6136577A | Biological production of ethanol from waste gases with Clostridium ljungdahlii | 655 |
| 3 | WO1998000558A1 | Biological production of acetic acid from waste gases | 576 |
| 4 | US5807722A | Biological production of acetic acid from waste gases with Clostridium ljungdahlii | 515 |
| 5 | US6340581B1 | Biological production of products from waste gases | 407 |
| 6 | WO2017165244A1 | Microorganisms and artificial ecosystems for the production of protein, food, and useful co-products from c1 … | 116 |
| 7 | US5986133A | Recovery of fermentation salts from dilute aqueous solutions | 95 |
| 8 | US6478965B1 | Recovery of fermentation salts from dilute aqueous solutions | 63 |
| 9 | US20150315599A1 | Methods and Systems for Methylotrophic Production of Organic Compounds | 59 |
| 10 | US20130210096A1 | Methods and Systems for the Production of Hydrocarbon Products | 59 |
Citation counts reward age inside a searched corpus — the earliest Clostridium waste-gas patents accumulated decades of citations and should be read as historically influential, not as current state of the art.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three patterns stand out once the counts are set against each other: concentration at the top, a technology mix skewed toward upstream biology and apparatus rather than downstream separation, and a filing curve that looks softer than it likely is.
The top of the field is narrow
Five assignees hold 194 of the 257 records in scope, and the top ten climb to 93.4%. For a new entrant, this means the core recovery and clarification claims around the leading strains are largely occupied; freedom-to-operate work should start by mapping exactly which claims those leaders hold rather than assuming open ground.
Apparatus and biology outweigh downstream separation
Bioreactor and microorganism claims each cover roughly two in five records, while classes tied more directly to gas-to-chemical conversion and inorganic recovery stay under 12%. That gap suggests the field has claimed how the organisms and vessels work more thoroughly than it has claimed how the product is pulled out and purified afterward.
A cooling curve, but read it carefully
The three-year run from 2021 to 2024 shows a 33% decline in filings, following a 2017 peak of 38. Because publication lags filing by about 18 months, the 2025-2026 figures are not yet reliable evidence of a further slowdown — treat the recent dip as a floor, not a ceiling.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to syngas fermentation product recovery, with the prior art for and against each one.
Who holds the ground, and where they overlap
The ranked leaders account for the overwhelming majority of filings, with a long tail of single- or few-filing entrants behind them. Co-assignee patterns point to a small number of tightly linked filing groups rather than broad industry-wide collaboration.
One filer sets the pace
The leading assignee's 68 records is roughly four times the fifth-place count of 17, a gap wide enough that its filing strategy effectively sets the baseline for what counts as claimed territory in gas fermentation recovery.
A steep drop after the leader
Filings fall off quickly outside the top few positions — fifth place holds 17 records and tenth place only 5 — which points to a small cluster of serious repeat filers surrounded by a long tail of entrants with one or two filings each.
Filing groups are tight, not broad
The strongest co-assignee links run through a small number of related entities and named inventors rather than across independent companies, suggesting most joint filings reflect internal corporate structure rather than cross-company partnership.
| Assignee | Recent year | YoY |
|---|---|---|
| LanzaTech NZ Inc | 0 | — |
| LanzaTech Inc | 0 | -100% |
| LANZATECH NZ INC | 0 | — |
| Synata Bio Inc | 0 | — |
| Kiverdi Inc | 0 | — |
| Texas A&M University | 0 | — |
| Ginkgo Bioworks Inc | 0 | — |
| String Bio | 0 | — |
Where to take this analysis
A landscape count tells you where the crowd is; it does not tell you whether a specific claim you want to file actually clears prior art. The next steps depend on whether you are scoping freedom-to-operate or looking for a place to file.
Map the leader's exact claim boundaries
With one assignee holding 68 of 257 records, a freedom-to-operate review should start by pulling that portfolio's independent claims before assuming any recovery method is open.
Explore assignee portfolios in EurekaStress-test white space candidates
The under-claimed branches flagged here are a starting point, not a conclusion — run a focused prior-art search on the specific mechanism before drafting.
Run a white space search in EurekaCommon questions about this landscape
One assignee leads the field with 68 of the 257 records in scope, roughly four times the count held by the fifth-ranked assignee at 17. The top five assignees combined account for 75.5% of all records, and the top ten reach 93.4%. This level of concentration means a small number of portfolios cover most of the documented recovery methods, so competitive mapping should focus there first rather than across the full 39-company ranking.
Filing peaked at 38 records in 2017 and complete-year data show a drop from 6 filings in 2021 to 4 in 2024, a 33% decline over that span. However, publication typically lags filing by about 18 months, so the apparent low counts in 2025 and 2026 are an artefact of that lag rather than confirmed evidence of a slowdown. The 2021-2024 window is the most reliable basis for judging the recent trend.
Both are recovery-stage steps captured in this dataset's search scope, but they sit at different points in the process: cell removal typically covers separating microbial biomass from the fermentation broth, while broth clarification covers the finer downstream step of removing residual solids and impurities before product capture. Neither is broken out as its own IPC subclass in the data, so distinguishing them requires reading claim language directly rather than relying on classification alone.
Within this 257-record dataset, C12M (bioreactors and enzyme apparatus) and C12N (microorganisms and genetic engineering) are the two largest classes after the defining C12P fermentation class, appearing in 41.2% and 40.5% of records respectively. Classes tied to inorganic gas chemistry (C01B) and electrolytic production (C25B) each appear in under 12% of records, indicating that apparatus and biology claims are more heavily staked than downstream separation chemistry.
WO2024228166A1, filed by CIRCE Biotechnologie GmbH and published in November 2024, covers acetogenic gas fermentation of carbon monoxide and related C1 substrates including CO2 and H2, using acetogens such as Thermoanaerobacter kivui in bioreactors. It represents a more recent filing than the highly-cited Clostridium-based foundational patents from the late 1990s, and its scope is centred on the fermentation substrate and organism rather than a specific downstream recovery mechanism. Anyone designing a recovery process around thermophilic acetogens should read its claims in full rather than relying on the abstract.
Research Syngas Fermentation Product Recovery in depth with Eureka
Go past this page: query the whole syngas fermentation product recovery corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.